Results from their machine learning-based analysis to be offered at The Molecular Medicine Tri-Conference in San Francisco.
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–February 13, 2018–
Cytobank and the U.S. Food and Drug Administration (FDA) are collaborating to develop machine learning-based strategies for characterizing the morphology of multipotent mesenchymal stromal cells (MSCs). These strategies could possibly be utilized in mobile manufacturing processes to characterize mobile preparations with desired immunotherapeutic properties.
The collaboration demonstrates the power of Cytobank’s cloud-based informatics platform to determine particular subpopulations from a combined inhabitants of MSCs and builds on work performed by Steve R. Bauer and colleagues from the FDA and revealed in PNAS, “The Morphological options of IFN-γ–stimulated mesenchymal stromal cells predict general immunosuppressive capability.” This paper discusses how an improved understanding of the morphological options of MSCs will complement present strategies for characterizing all these cell preparations, that are utilized in medical purposes involving immunomodulation.
“Machine learning-based approaches like these we’re growing with the FDA have been utilized by our analysis clients for years to construct their understanding of the immune system on the single cell stage. We are excited by the potential to use our confirmed analysis approaches in additional improvement associated purposes, together with cell characterization,” mentioned David Craford, President and Chief Executive Officer of Cytobank.
Human MSCs are utilized for a number of medical purposes in regenerative drugs together with coronary heart, bone, and neurological circumstances. There are roughly 650 medical trials underway globally. According to Grand View Research the worldwide stem cell market income is presently estimated at USD $7B and anticipated to succeed in $15B by 2025.
Dr. Katherine Drake, Director of Informatics at Cytobank, will current outcomes from the analysis in her presentation entitled “Uncovering Hidden Single Cell Biomarkers with Machine Learning” on the Molecular Medicine Tri-Conference Symposium on Single Cell Analysis in San Francisco on February 15, 2018 at 3:00 PM.
About the FDA
The FDA, an company throughout the U.S. Department of Health and Human Services, protects the general public well being by assuring the security, effectiveness, and safety of human and veterinary medicine, vaccines, and different organic merchandise for human use, and medical units. The company is also answerable for the security and safety of our nation’s meals provide, cosmetics, dietary dietary supplements, merchandise that give off digital radiation, and for regulating tobacco merchandise.
Cytobank Inc. is the main cloud-based evaluation platform using machine studying algorithms for collaborative biomedical analysis. Prominent pharmaceutical, biotechnology, and tutorial researchers round the world use their SaaS resolution to develop deep understandings of complicated biology on the single cell stage. For extra info, please go to https://www.cytobank.org/.
Liz Johannesen, 415-613-2497
This article sources info from VentureBeat